MA27565A1 - Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur - Google Patents

Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur

Info

Publication number
MA27565A1
MA27565A1 MA28335A MA28335A MA27565A1 MA 27565 A1 MA27565 A1 MA 27565A1 MA 28335 A MA28335 A MA 28335A MA 28335 A MA28335 A MA 28335A MA 27565 A1 MA27565 A1 MA 27565A1
Authority
MA
Morocco
Prior art keywords
tetrazolyl
treatment
methods
phenylpiperidine
pain
Prior art date
Application number
MA28335A
Other languages
English (en)
French (fr)
Inventor
Zhengming Chen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of MA27565A1 publication Critical patent/MA27565A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA28335A 2002-11-18 2005-06-13 Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur MA27565A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42738102P 2002-11-18 2002-11-18
US46027803P 2003-04-03 2003-04-03
US48848803P 2003-07-17 2003-07-17
US10/714,066 US7202259B2 (en) 2002-11-18 2003-11-13 Therapeutic agents useful for treating pain

Publications (1)

Publication Number Publication Date
MA27565A1 true MA27565A1 (fr) 2005-10-03

Family

ID=32777221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28335A MA27565A1 (fr) 2002-11-18 2005-06-13 Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur

Country Status (36)

Country Link
US (3) US7202259B2 (https=)
EP (2) EP1562932B9 (https=)
JP (2) JP4601429B2 (https=)
KR (1) KR20050115221A (https=)
CN (2) CN100567288C (https=)
AP (1) AP2210A (https=)
AR (1) AR047008A1 (https=)
AT (2) ATE358674T1 (https=)
AU (2) AU2003294313B2 (https=)
BR (1) BR0316305A (https=)
CA (1) CA2506242C (https=)
CO (1) CO5690588A2 (https=)
CR (2) CR7877A (https=)
CY (2) CY1107682T1 (https=)
DE (2) DE60313021T2 (https=)
DK (2) DK1803718T3 (https=)
EA (1) EA008621B1 (https=)
EC (1) ECSP055840A (https=)
ES (2) ES2285235T3 (https=)
GE (1) GEP20084539B (https=)
IL (1) IL209352A0 (https=)
IS (2) IS2720B (https=)
MA (1) MA27565A1 (https=)
ME (1) MEP48108A (https=)
MX (1) MXPA05004669A (https=)
MY (1) MY135647A (https=)
NI (1) NI200500087A (https=)
NO (1) NO20052894L (https=)
NZ (2) NZ572685A (https=)
OA (1) OA13010A (https=)
PT (2) PT1803718E (https=)
RS (1) RS51047B (https=)
SG (1) SG165998A1 (https=)
SI (2) SI1562932T1 (https=)
TW (2) TWI343917B (https=)
WO (1) WO2004046132A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
RS20050812A (sr) 2003-04-30 2007-12-31 Purdue Pharma L.P., Transdermalni dozni oblik otporan na promene
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
KR100886002B1 (ko) 2004-01-30 2009-03-03 유로-셀띠끄 소시에떼 아노님 4-테트라졸릴-4-페닐피페리딘 화합물의 제조방법
SE0401656D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
PT1951718E (pt) * 2005-11-21 2012-05-21 Purdue Pharma Lp Compostos de 4-oxadiazolil-piperidina e as suas utilizações
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
WO2011056561A1 (en) 2009-10-27 2011-05-12 Beth Israel Deaconess Medical Center Methods and compositions for the generation and use of conformation-specific antibodies
ES2566828T3 (es) 2010-09-21 2016-04-15 Purdue Pharma L.P. Análogos de buprenorfina como agonistas y/o antagonistas del receptor opioide
CN102648915B (zh) * 2011-02-28 2015-04-15 鲁南制药集团股份有限公司 一种治疗或预防神经病理性疼痛的药物组合物
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
EP2917182B1 (en) 2012-11-09 2018-01-03 Purdue Pharma LP Benzomorphan analogs and the use thereof
WO2014087226A1 (en) 2012-12-07 2014-06-12 Purdue Pharma L.P. Buprenorphine analogs as opiod receptor modulators
WO2014091297A1 (en) 2012-12-14 2014-06-19 Purdue Pharma L.P. Spirocyclic morphinans and their use
EP2931724B1 (en) 2012-12-14 2017-01-25 Purdue Pharma LP Pyridonemorphinan analogs and biological activity on opioid receptors
JP6182620B2 (ja) 2013-01-31 2017-08-16 パーデュー、ファーマ、リミテッド、パートナーシップ ベンゾモルファン類似体およびその使用
US8969358B2 (en) 2013-03-15 2015-03-03 Purdue Pharma L.P. Buprenorphine analogs
WO2015097545A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Opioid receptor modulating oxabicyclo[2.2.2]octane morphinans
WO2015097546A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. Propellane-based compounds and their use as opioid receptor modulators
WO2015097547A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 10-substituted morphinan hydantoins
WO2015097548A1 (en) 2013-12-26 2015-07-02 Purdue Pharma L.P. 7-beta-alkyl analogs of orvinols
EP3087057A4 (en) 2013-12-26 2017-06-28 Purdue Pharma LP Ring-contracted morphinans and the use thereof
WO2015099863A1 (en) 2013-12-27 2015-07-02 Purdue Pharma L.P. 6-substituted and 7-substituted morphinan analogs and the use thereof
CA2950567A1 (en) 2014-05-27 2015-12-03 Purdue Pharma L.P. Spirocyclic morphinans and use thereof
MA40171A (fr) 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
MA41125A (fr) 2014-12-05 2017-10-10 Purdue Pharma Lp Dérivés de 6.7-cyclomorphinane et leur utilisation
US11529340B2 (en) 2016-03-22 2022-12-20 Regents Of The University Of Minnesota Combination for treating pain
UA124972C2 (uk) 2016-07-29 2021-12-22 Янссен Фармацевтика Нв Способи лікування раку передміхурової залози
WO2018125716A1 (en) 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
MX2023013514A (es) * 2021-05-21 2024-04-02 Purdue Pharma Lp Metodos para tratar la cistitis intersticial/sindrome de dolor en la vejiga.
KR20250026332A (ko) * 2022-06-24 2025-02-25 퍼듀 퍼머 엘피 과민성 방광 증후군의 치료 또는 예방 방법

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
BE775611A (fr) 1970-11-24 1972-03-16 Synthelabo Derives de la (diphenyl-3,3 propyl-1)-1 piperidine, leur preparation etles medicaments qui en contiennent
US4076717A (en) * 1971-12-15 1978-02-28 G. D. Searle & Co. Derivatives of 1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
US4831192A (en) * 1987-12-31 1989-05-16 Boc, Inc. Methods of preparing 4-heteropentacyclic-4-(N-phenyl)amido) piperidine derivatives and intermediate compounds
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5698155A (en) * 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5449989A (en) 1992-07-31 1995-09-12 Correa; Paulo N. Energy conversion system
US5606037A (en) 1992-11-09 1997-02-25 Biochem Pharma Inc. Processes antineoplastic heteronaphthoquinones
US5736523A (en) 1992-11-09 1998-04-07 Biochem Pharma Inc. Antineoplastic heteronapthoquinones
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5849737A (en) 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
US6166085A (en) 1995-04-14 2000-12-26 The Regents Of The University Of California Method of producing analgesia
ES2247604T3 (es) * 1995-06-12 2006-03-01 G.D. SEARLE & CO. Composiciones que comprenden un inhibidor de ciclooxigenasa-2 y un inhibidor de 5-lipoxigenasa.
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
WO1997024325A1 (en) 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DIPHENYLMETHANE DERIVATIVES AS MIP-1α/RANTES RECEPTOR ANTAGONISTS
US6221888B1 (en) 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
SK283394B6 (sk) * 1997-06-10 2003-07-01 Synthon B. V. Zlúčeniny 4-fenylpiperidínu a jej farmaceuticky prijateľné soli, spôsob ich prípravy, liečivo s ich obsahom a ich použitie
EP1058684A1 (en) 1998-03-06 2000-12-13 Janssen Pharmaceutica N.V. Glycine transport inhibitors
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
PE20001420A1 (es) 1998-12-23 2000-12-18 Pfizer Moduladores de ccr5
US7217714B1 (en) 1998-12-23 2007-05-15 Agouron Pharmaceuticals, Inc. CCR5 modulators
ATE278674T1 (de) 1999-03-12 2004-10-15 Boehringer Ingelheim Pharma Heterocyklischer harnstoff und verwandte verbindungen als entzündungshemmende mittel
WO2001021169A1 (en) 1999-09-20 2001-03-29 Takeda Chemical Industries, Ltd. Mch antagonists
CA2324330A1 (en) 1999-11-08 2001-05-08 Ssp Co., Ltd. 4-hydroxy-4-phenylpiperidine derivatives and pharmaceuticals containing the same
AU1816901A (en) 1999-12-06 2001-06-12 Euro-Celtique S.A. Benzimidazole compounds having nociceptin receptor affinity
US6486142B2 (en) 1999-12-22 2002-11-26 Merck Frosst Canada & Co. Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B)
US6703525B2 (en) 2000-02-16 2004-03-09 Boehringer Ingelheim Pharmaceuticals, Inc. Sulfonamide intermediates and methods of producing same
US6608052B2 (en) 2000-02-16 2003-08-19 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
CA2404280A1 (en) 2000-03-24 2002-09-23 Meiji Seika Kaisha, Ltd. Diphenylalkylamine derivatives useful as opioid .delta. receptor agonists
US6544981B2 (en) 2000-06-09 2003-04-08 Bristol-Myers Squibb Company Lactam inhibitors of factor Xa and method
JPWO2002030896A1 (ja) 2000-10-12 2004-02-19 エスエス製薬株式会社 2,2−ジフェニルブタンアミド誘導体及びこれを含有する医薬
WO2002038185A2 (en) 2000-11-13 2002-05-16 Atrix Laboratories, Inc. Injectable sustained release delivery system with loperamide
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
KR100886002B1 (ko) * 2004-01-30 2009-03-03 유로-셀띠끄 소시에떼 아노님 4-테트라졸릴-4-페닐피페리딘 화합물의 제조방법

Also Published As

Publication number Publication date
NZ572685A (en) 2010-06-25
US7687518B2 (en) 2010-03-30
NO20052894D0 (no) 2005-06-14
CR11037A (es) 2009-10-29
RS20050375A (sr) 2007-11-15
CN1711256A (zh) 2005-12-21
AU2003294313B2 (en) 2010-08-26
DK1803718T3 (da) 2008-10-27
JP2010163452A (ja) 2010-07-29
ATE402167T1 (de) 2008-08-15
CY1107682T1 (el) 2013-04-18
DE60313021T2 (de) 2007-12-13
KR20050115221A (ko) 2005-12-07
JP4601429B2 (ja) 2010-12-22
PT1803718E (pt) 2008-09-26
TW200819436A (en) 2008-05-01
US20040152689A1 (en) 2004-08-05
EA200500726A1 (ru) 2005-10-27
CA2506242C (en) 2011-07-05
PT1562932E (pt) 2007-07-02
AR047008A1 (es) 2006-01-04
US7202259B2 (en) 2007-04-10
DE60322451D1 (de) 2008-09-04
OA13010A (en) 2006-11-10
GEP20084539B (en) 2008-11-25
CY1108422T1 (el) 2014-04-09
DE60313021D1 (de) 2007-05-16
TW200418828A (en) 2004-10-01
IL209352A0 (en) 2011-01-31
CO5690588A2 (es) 2006-10-31
MY135647A (en) 2008-06-30
IS8913A (is) 2010-07-21
CR7877A (es) 2005-11-30
IS2720B (is) 2011-02-15
CA2506242A1 (en) 2004-06-03
RS51047B (sr) 2010-10-31
NO20052894L (no) 2005-06-14
SG165998A1 (en) 2010-11-29
MXPA05004669A (es) 2005-06-08
EP1562932A1 (en) 2005-08-17
ES2285235T3 (es) 2007-11-16
CN100567288C (zh) 2009-12-09
ES2312150T3 (es) 2009-02-16
EA008621B1 (ru) 2007-06-29
AU2003294313A1 (en) 2004-06-15
SI1803718T1 (sl) 2008-12-31
ECSP055840A (es) 2005-08-11
NZ540068A (en) 2007-07-27
JP2006525944A (ja) 2006-11-16
US20100069437A1 (en) 2010-03-18
EP1803718A1 (en) 2007-07-04
HK1086829A1 (zh) 2006-09-29
IS7812A (is) 2005-04-19
DK1562932T3 (da) 2007-08-13
US8026254B2 (en) 2011-09-27
AP2210A (en) 2011-02-25
MEP48108A (en) 2011-02-10
NI200500087A (es) 2007-07-24
WO2004046132A1 (en) 2004-06-03
AU2010246411A1 (en) 2010-12-16
BR0316305A (pt) 2005-09-27
EP1803718B1 (en) 2008-07-23
EP1562932B1 (en) 2007-04-04
ATE358674T1 (de) 2007-04-15
SI1562932T1 (sl) 2007-08-31
EP1562932B9 (en) 2007-09-12
US20070179141A1 (en) 2007-08-02
TWI343917B (en) 2011-06-21
CN101648941A (zh) 2010-02-17
AP2005003297A0 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
MA27565A1 (fr) Derives de 4-tetrazolyl-4-phenylpiperidine utilises pour le traitement de la douleur
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA28681B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
MA28680B1 (fr) 3-aminocyclopentanecarboxamides utiles comme modulateurs de récepteurs de chimiokines
TN2009000138A1 (fr) Biaryl-ether-urees
MXPA04006280A (es) Compuestos espiroazaciclicos como moduladores de receptor de monoamina.
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
EA200100203A1 (ru) Производные 4,4-биарилпиперидина с активностью в отношении опиоидных рецепторов
MA32232B1 (fr) Nouveaux compoés hétérocycliques et leurs utilisations
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
EA200501504A1 (ru) Лиганды каннабиноидных рецепторов и их применение
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
BRPI0307355C1 (pt) composto de 2,4-pirimidinodiamina, e, composição farmacêutica compreendendo o mesmo
BRPI0407375A (pt) Métodos para tratar dor por meio da administração de um antagonista do fator de crescimento neural e u nsaid e composições contendo os mesmos
DK1461318T3 (da) Tetrahydroquinolinanaloge som muscariniske agonister
MA33836B1 (fr) Compositions pharmaceutiques contenant des ligands des récepteurs sigma
MA27448A1 (fr) Derives de pyridine modulateurs du recepteur cb2
ATE389395T1 (de) Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
ATE357917T1 (de) Behandlung von dyskinesie durch mu-selektive opioidantagonisten
TW200624430A (en) 4-(heteroaryl-methyl and substituted heteroaryl-methyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists
TW200626146A (en) 4-(condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists